DigiVidBIO helps companies grow by leveraging data-driven digital advertising and video strategies!
Phoenix, Arizona
Joined May 2023
- Tweets666
- Following248
- Followers32
- Likes780
DigiVidBio retweeted
Marketing engagement is more valuable when sales can act on it.
Kuros Biosciences bridges the gap with monthly #surgeon-level insights, giving regional reps 400+ warm leads to explore.
Discover the approach: digividbio.com/casestudies/n…
#NPItargeting
DigiVidBio retweeted
A physician’s media journey doesn’t happen on one screen.
NPI-based identity resolution connects the dots across display, mobile, and CTV—so every interaction can build on the last.
That’s when #video becomes a compounding advantage.
Read the blog: digividbio.com/blogs/why-vid…
DigiVidBio retweeted
Natera is proud to announce our national partnership with Susan G. Komen®, the world's leading breast cancer organization.
As the 2026 Premier National Series Sponsor of the Susan G. Komen Race for the Cure® and MORE THAN PINK Walk® events, we're working to accelerate breast cancer awareness, education, and understanding of molecular residual disease (MRD) testing.
“We are honored to support Komen’s national event series and stand alongside the patients, advocates, researchers, and healthcare professionals working every day to improve outcomes for people affected by breast cancer,” said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection at Natera.
Read the full announcement here: ow.ly/WoII50ZGANu
@SusanGKomen
DigiVidBio retweeted
Community oncologist Dr. José Alemar shares how Signatera™ MRD testing can help detect cancer recurrence earlier than standard of care tools.
Learn more: ow.ly/Q68C50ZybwH
DigiVidBio retweeted
Over the weekend, several Natera employees joined >1,000 participants at the @rideaudaxity cycling event in Milwaukee to help advance cancer research and personalized care.
This year marked the second annual ride with the goal to double last year's fundraising of over $1 million. 100% of all donations go directly to funding research at the Medical College of Wisconsin (MCW) Cancer Center.
To everyone who rode, volunteered, cheered from the sidelines, or donated — thank you. We're proud to sponsor this event and the groundbreaking research happening at MCW.
ow.ly/FA2650ZwFMt
DigiVidBio retweeted
In an interview with Technology Networks, Dr. Rebecca Critchley-Thorne, vice president of R&D at Castle Biosciences, discussed how AI-enabled spatial proteomics differs to traditional spatial proteomics, TissueCypher’s impact on BE management, and its broader potential for precision oncology. technologynetworks.com/tn/bl…
DigiVidBio retweeted
Join our upcoming webinar to explore real-world case studies and gain practical nursing strategies for managing complex transplant cases.
You'll learn:
• Real-world case studies demonstrating clinical implications of high-risk Prospera results
• How to interpret the Prospera report and determine the next steps in patient management
• How Natera’s Clinical Nurse Coordinators (CNCs) can support your nurses through detailed case reviews
🔗 Register here: ow.ly/OFia50WSaOg
#Natera #Prospera #Transplant #Nurses #CNC
DigiVidBio retweeted
realtalkms.com/418
Last week, the UAE became the first country in the world to approve Tolebrutinib for adults with non-relapsing secondary progressive MS. Tolebrutinib represents a new category of disease-modifying therapy that has people excited. We're talking about why. On RealTalk MS #MultipleSclerosis @Sanofi
DigiVidBio retweeted
realtalkms.com/413 A study shows what can happen when you delay starting a disease-modifying therapy. We’re sharing the details on RealTalk MS. #MultipleSclerosis
DigiVidBio retweeted
We are pleased to share a recent publication from #LabPMM, covering interpretation, tracking and reporting of #KMT2A fusions in #AML. Read the full publication here: hubs.li/Q03zPZC20
#MeninInhibitors #Drugdevelopment #MyMRD #MyAML
DigiVidBio retweeted
Last week we enjoyed hosting Colorado BioScience Association’s Drive to Five tour at our Lakewood HQ! A great day of connection, innovation, and showcasing how our tech is making a global impact on patients.
#TerumoBCTSummerSchool #CoBioScience #StrongerTogether @cobioscience
DigiVidBio retweeted
Castle's DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). DecisionDx-Melanoma is a gene expression profile (GEP) test that provides comprehensive, personalized results to guide risk-aligned management decisions for patients diagnosed with stage I-III cutaneous melanoma.
The FDA grants Breakthrough Device designation to select qualifying devices that may offer improved treatment or diagnosis of life-threatening or irreversibly debilitating diseases when compared to currently available alternatives. Details: hubs.la/Q03yw18T0
DigiVidBio retweeted
Say goodbye to subjectivity. See how IdentiClone® RUO TCRG 2.0 delivers automated, standardized clonality calls with expert-level accuracy. Check out our poster at #ADLM2025.
Learn more: hubs.li/Q03y2mdt0
ALT A Comparison of Clinical Expert to Software Analysis of T-Cell Receptor Gamma Gene Rearrangement Capillary Electrophoresis Datasets
ALT Identiclone RUO TCRG 2.0 Software: Rapid Analysis, Objective Interpretation, Accurate Results
DigiVidBio retweeted
realtalkms.com/412 What is it like to live with MS? What are you hoping for in future treatments? The FDA wants to hear from you! Find out how and where to register for an informational webinar that will cover all the details about the Shaping Tomorrow Together initiative on RealTalk MS. #MultipleSclerosis
DigiVidBio retweeted
Big news as we announce our new agreement w/ @VWR to bring Next-Generation Protein Sequencing™ to more researchers across the U.S. and Canada in 2025! Together, we’re transforming proteomics research w/ groundbreaking insights. Read: bit.ly/3OhmpY9 @Jeff_Hawkins_MI
DigiVidBio retweeted
📣 Happy National Radiologic Technology Week! 📣
This week, we’re celebrating the incredible radiologic technologists who bring skill, care, and compassion to patient care every day. Thank you for all that you do! 💙
#nationalradtechweek #radiologictechnology #radiationtherapy
DigiVidBio retweeted
realtalkms.com/375 Dr. Ann Yeh joins me to discuss how MS affects adolescents and how families can help manage MS on RealTalk MS. #MultipleSclerosis
DigiVidBio retweeted
We also announced that we’ve entered into an agreement to acquire @AmbryGenetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.
Today, we shared our Q3 earnings:
• Revenue increased 33.0% year-over-year to $180.9 million in the third quarter of 2024
• Data and services revenue growth accelerated to 64.4% year-over-year
• Genomics unit growth accelerated to 23.9% annually with rising average revenue per clinical test
• Adjusted EBITDA improved $14.4 million year over year to $(21.8 million)
• Expected full year 2024 revenue of ~$700 million, which represents ~32% annual growth
Learn more: tempus.co/3YCDuR2
DigiVidBio retweeted
For patients with cancer, the earlier you track the better prepared you can be.
Watch the video below (@OlgaAlexeeva16) to discover how NeXT Personal® is able to detect cancer recurrence earlier through the identification of circulating tumor DNA (ctDNA).
#PrecisionOncology #LiquidBiopsy #MRD #ctDNA